Technological Exhibition – Health Innovation

Do not miss AIBILI’s speakers at the roundtables on Personalised Medicine (Inês Pereira Marques) and Big Data/Artificial Intelligence (Luis Mendes).

This Friday, September 16th during the Technology Exhibition dedicated to Health Innovation organised by the Coimbra University and AIBILI.

More information here: https://www.uc.pt/ucbusiness/inovacao-em-saude/

AIBILI has been recognized as a Technology and Innovation Center

AIBILI has been recognized as a Technology and Innovation Center.
The Technology and Innovation Centers (CTI) are entities dedicated to the production, dissemination and transmission of knowledge, oriented to companies and the creation of economic value, contributing, to the pursuit of public policy objectives, framed in the areas of national priority expertise or regions in which they operate.
ANI was responsible for this process that falls under the Recovery and Resilience Program (PRR).
More information: https://files.dre.pt/2s/2022/08/152000002/0000200003.pdf

Prof. José Cunha-Vaz receives the Arnall Patz Medal

The Honorary President of AIBILI, Prof. José Cunha-Vaz, was distinguished today, June 9th, in Berlin, Germany, with the Arnall Patz Medal. The Arnall Patz Medal is intended to distinguish outstanding contributions to the study of Retinal Vascular Diseases. The ceremony took place during the 45th Congress of the Macula Society.

This distinction is recognition of the scientific career and clinical research activity of José Cunha-Vaz, evident in his innovative contributions, which over the years have greatly contributed to the knowledge and treatment of retinal diseases, and more particularly diabetic retinopathy, a leading cause of blindness.

Azores Health Summit

AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic retinopathy screening programmes using artificial intelligence. This participation will be complemented by João Diogo Ramos from our partnering company Retmarker SA.

US Patent published representing another major milestone in AIBILI’s history (US 11,2354,591 B2)

We are honoured to see our recent US Patent published representing another major milestone in AIBILI’s history. This patent US 11,2354,591 B2 follows the EU Patent EP3289565A1 that was received in August 2020.

The team lead by the inventors José Cunha-Vaz and Torcato Santos have developed a method and device that detects and quantifies abnormal increases of retinal extra cellular space using sites of low optical reflectivity from optical coherence tomography (OCT).

This non-invasive method detects changes in the blood-retinal barrier enabling timely treatment and therapy validation in the early stages of diabetic retinopathy.

Dia Internacional dos Ensaios Clinicos – Investigação Clinica em Portugal

Do not miss the opportunity to hear about AIBILI Data Centre and its relevance for clinical research development.

Carlos Domingues, AIBILI DataCentre Director will participate in this conference taking place on May 19, 2022, in Porto, Portugal.

This AIBILI infrastructure is the unique DataCentre in the Peninsula Iberia certified by ECRIN.

Claudia Farinha and Patrícia Barreto were awarded with Prémio Plácido of the Portuguese Ophthalmology Society

Congratulations to our Investigators Cláudia Farinha and Patrícia Barreto that were awarded with the Prémio Plácido during the 64th Congress of the Portuguese Ophthalmology Society with the paper GENETIC CHARACTERIZATION OF AMD IN THE COIMBRA EYE STUDY – Common and Rare Risk Variants & Genetic Risk Score (GRS) .

 

This is the first genetic study in AMD in a Portuguese population. According to our results, several variants were found to be associated with the presence and progression to AMD in our cohort, while others were protective. Furthermore, damaging rare variants in the CFH gene were cumulatively more common in AMD patients and the GRS was significantly different between AMD and non-AMD individuals. Our study adds new information regarding the genetics of AMD in a European population, which can be used for comparison with other populational cohorts and further expand the knowledge of AMD pathophysiology.